Please login to the form below

Not currently logged in
Email:
Password:

Roche to cease HIV research

Roche, the Swiss pharmaceutical company, is to cease research into HIV as none of its pending medicines represent a significant improvement over existing drugs
Roche, the Swiss pharmaceutical company, is to cease research into HIV as none of its pending medicines represent a significant improvement over existing drugs.

A report, published by Reuters, references a memo sent to Aids specialists and activists saying that, due to poor results in clinical trials, the company had cancelled its current product development programmes.

Confirming the contents of the memo, a spokeswoman based in Roche's US office said the company has "decided to refocus our resources within virology on diseases in which we can deliver substantial improvements over existing medications."

"Research scientists currently working in HIV will be reassigned to other activities," said the spokeswoman.

According to figures published by independent market research firm, Datamonitor, a small increase in HIV cases and the launch of new drugs means that the AIDS medicine market is set to be worth $10.6bn by 2015.

According to the report, Roche said it would reassess its involvement in this area should a scientific breakthrough in HIV occur elsewhere. The company has vowed to continue supporting its molecular diagnostic tests and medications already on the market.

14th July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics